BIT
ATXS

BlackRock Institutional Trust’s Astria Therapeutics ATXS Stock Holding History

BlackRock Institutional Trust’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-281
Closed -$85K – 3886
2016
Q1 		$85K Sell
281
-8
-3% -$2.76K ﹤0.01% 3741
2015
Q4 		$138K Buy
289
+129
+81% +$61.9K ﹤0.01% 3708
2015
Q3 		$78K Buy
+160
New +$114K ﹤0.01% 3761

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BlackRock Institutional Trust's ATXS Position: Q2 2016 in Review

BlackRock Institutional Trust sold out of Astria Therapeutics (ATXS) in Q2 2016, closing a stake of 281 shares — an estimated $85K sold.

BlackRock Institutional Trust first reported a position in ATXS in Q3 2015 and held it in 3 quarters. The position peaked at $138K in Q4 2015. 27 funds tracked by Wall St. Rank hold ATXS as of Q2 2016.

  • BlackRock Institutional Trust reported no remaining Astria Therapeutics position as of Q2 2016 after selling out during the quarter.
  • BlackRock Institutional Trust sold 281 Astria Therapeutics shares in Q2 2016, an estimated $85K.
  • BlackRock Institutional Trust first reported a position in Astria Therapeutics in Q3 2015 and held it in 3 quarters.
  • BlackRock Institutional Trust's Astria Therapeutics position peaked at $138K in Q4 2015.
  • 27 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2016.

Based on BlackRock Institutional Trust's 13F filing for Q2 2016, filed 10 Aug 2016.